Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis

Abstract

<b><i>Background:</i></b> Allergic diseases are a public health problem with the largest number of patients and the widest age distribution. Chronic urticaria (CU) is a common clinical allergic disease. Bilastine is effective in the treatment of CU, especially skin wind masses and erythema. The purpose of this study was to systematically evaluate the efficacy and safety of Bilastine in the treatment of CU symptoms and to provide an evidence-based reference for clinical rational drug use. <b><i>Methods:</i></b> PubMed, Scopus, the Cochrane Library, Embase, EBSCO, and other databases were searched by computer to collect the trials on the effect of bilastine on patients with CU. The retrieval time limit was established until November 2021. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias in the included study. Meta-analysis was performed using RevMan5.4 software. <b><i>Results:</i></b> A total of 7 studies were included, including 975 patients. Meta-analysis results showed that compared to the control group, bilastine significantly improved the skin quality of life index, Total Symptom Score (TSS), and weekly urticaria activity score. The skin quality of life index DLQI score (MD = −4.98, 95% CI: −8.09 to −1.86, <i>p</i> = 0.002), skin symptom score TSS (MD = −1.62, 95% CI −2.29 to −0.94, <i>p</i> < 0.00001), the number of hives in a week UAS-7 score (MD = −25.28, 95% CI −32.36 to −18.19, <i>p</i> < 0.00001), and the differences were statistically significant. <b><i>Conclusions:</i></b> Bilastine has a better therapeutic effect on CU and can also significantly improve the clinical symptoms and quality of life of CU.

Repurposing the antihistamine drug bilastine as an anti-cancer metallic drug entity: synthesis and single-crystal X-ray structure analysis of metal-based bilastine and phen [Co(ii), Cu(ii) and Zn(ii)] tailored anticancer chemotherapeutic agents against resistant cancer cells

“…), is an active antihistamine drug, sold under the trade name Bilaxten® for allergic rhinoconjunctivitis and chronic urticaria. [1][2][3][4] Repurposing drugs for the treatment of other chronic diseases including cancer is a recent technological niche to utilize the resources of 'active' pharmaceuticals for remedies with improved therapeutic responses and better pharmacokinetic profiles than that of existing drugs. 5,6 Previous reports in the literature have revealed the strong relevance of histamines to the regulation of several tumors such as cervical, ovarian, uterine, colorectal cancer and melanoma by promoting or inhibiting their growth.…”

Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial

“…This aligns with a meta-analysis underscoring bilastine’s efficacy in symptom control and QoL enhancement. [ 5 ] Nevertheless, morning administration may lead to heightened somnolence in the levocetirizine group. This study demonstrated that bilastine significantly alleviated physical discomfort from chronic idiopathic urticaria, and might enhance participants’ QoL and sleep.…”